Soticlestat
- Generic Name
- Soticlestat
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C23H23N3O2
- CAS Number
- 1429505-03-2
- Unique Ingredient Identifier
- 1766MU795L
- Associated Conditions
- -
- Associated Therapies
- -
A Multicenter, Open-label, Pilot Study of Soticlestat (TAK-935/OV935) in Participants With 15Q Duplication Syndrome (Dup 15q) or Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder (ARCADE STUDY)
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2018-10-03
- Last Posted Date
- 2022-05-26
- Lead Sponsor
- Takeda
- Target Recruit Count
- 20
- Registration Number
- NCT03694275
- Locations
- 🇺🇸
Center for Rare Neurological Diseases, Norcross, Georgia, United States
🇺🇸Research Institute Children's Hospital Colorado, Aurora, Colorado, United States
🇺🇸Center for Rare Neurological Diseases (CRND)--Massachusetts General Hospital, Boston, Massachusetts, United States
A Study of Soticlestat in Adults and Children With Rare Epilepsies
Phase 2
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2018-08-17
- Last Posted Date
- 2024-02-21
- Lead Sponsor
- Takeda
- Target Recruit Count
- 156
- Registration Number
- NCT03635073
- Locations
- 🇺🇸
Center for Rare Neurological Diseases, Norcross, Georgia, United States
🇨🇦Hospital for Sick Children, Toronto, Ontario, Canada
🇮🇱Tel Aviv Sourasky Medical Center PPDS, Tel Aviv, Israel
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath